Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 17 Feb 2023
Online dating has revolutionized dating by creating more opportunities to meet partners than ever before.
Read Full NewsCould timing prostate cancer radiotherapy according to patients’ circadian rhythm genes reduce the risk for late side effects?
Progression-free survival with the multitarget PAM inhibitor approaches 10 months after anti-CDK4/6 and aromatase inhibitor failure.
Researchers retrospectively analyzed outcomes for 50 patients with biopsy-proven monoclonal gammopathy of renal significance for a median follow-up of 6.15 years.
In a small single-center study, 1-year survival is 100% among carefully selected patients who undergo bilateral lung transplantation for stage IV disease confined to the lungs.
1.
Retired Olympic athletes at greater risk of skin cancer and osteoarthritis, research reveals
2.
Medicaid expansion tied to smaller declines in early-stage cancer detection
3.
Many Americans unaware of links between HPV and cancers, poll reveals
4.
Frontline Decisions in Transplant-Ineligible Multiple Myeloma: Evaluating Quadruplet Therapy
5.
Pooled Cord Blood Transplants Achieve Near-Perfect Results in Early Trial
1.
Living with Shwachman-Diamond Syndrome: A Journey of Hope and Strength
2.
Unlocking the Potential of Glofitamab: A Novel Treatment for Cancer
3.
Optimizing Chemotherapy Dosing: From Phase 1 Dose Escalation to Modification
4.
Rare Malignant Ovarian Tumors: A Comprehensive Review for Clinicians
5.
Hematopoietic Clonal Competition in Blood Disorders
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Virtual Case Study on Pedal Edema and Triple Vessel Disease - An Initiative by Hidoc Dr.
2.
Understanding Early Relapse in B-cell ALL: Rates, Risks, and Common Sites
3.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part I
4.
Redefining Treatment Pathways in Relapsed/Refractory Adult B-Cell ALL
5.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma - Part V
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge